IWMF Correlative Companion Research Grants

IWMF Correlative Companion Research Grants

Status: ACTIVE
Funder: The International Waldenstrom's
Amount: Up to US $250,000
Last Updated: December 23, 2025

Summary

Overview

About Us The International Waldenstrom’s Macroglobulinemia Foundation (IWMF) is a patient-founded and patient-driven, nonprofit organization that is dedicated to a simple but compelling vision and mission. Our Vision A World without Waldenstrom’s macroglobulinemia (WM). Our Mission Support and educate everyone affected by Waldenstrom’s macroglobulinemia (WM) to improve patient outcomes while advancing the search for a cure. Applying for a Research Grant IWMF seeks applications for research and clinical studies that will deliver meaningful therapeutic benefits for Waldenstrom macroglobulinemia (WM) patients within the next 3–5 years. Grant amounts range from $250K–$1M over 2–4 years, with a separate award to support young investigators. Working in partnership with our world-class Scientific Advisory Committee, IWMF has developed an updated 2026 Strategic Research Agenda to advance innovative discoveries, support novel clinical trials, and foster collaborations that will continue to revolutionize treatments for WM. IWMF Correlative Companion Research Grants IWMF seeks to support correlative companion research studies within pharmaceutical and biotechnology company-sponsored trials for Waldenstrom macroglobulinemia (WM) patients that will be instrumental in determining the optimal use of new therapeutics under study. These projects leverage biological samples collected during trials to explore and validate biomarkers, mechanisms of response or resistance, or disease biology response to therapeutic intervention that will inform future clinical studies. Projects may include identifying genetic, proteomic, or immune markers that predict activity profiles, elucidating molecular mechanisms of resistance, TME profiling, MRD assessment, among others. These proposals are intended to leverage clinical research questions not funded by the industry sponsor and deemed critical for improving patient outcomes. Under this Grant program, the IWMF seeks to support companion studies within pharmaceutical and biotechnology company-sponsored trials for Waldenstrom macroglobulinemia (WM) that will be instrumental in determining the optimal use of new therapeutics under study. These projects leverage biological samples collected during trials to explore and validate biomarkers, mechanisms of response or resistance, or disease biology response to therapeutic intervention that will inform future clinical studies. Projects may include identifying genetic, proteomic, or immune markers that predict activity profiles, elucidating molecular mechanisms of resistance, TME profiling, MRD assessment, among others. These proposals are intended to leverage clinical research questions not funded by the industry sponsor and deemed to be critical for advancing the field of WM patient clinical outcomes.

Eligibility

You can learn more about this opportunity by visiting the funder's website. Applicants must hold an MD, PhD, or equivalent degree and work in domestic or foreign non-profit organizations, such as universities, colleges, hospitals, or laboratories.Applicants should have an independent research or academic position. Applicants need not be U.S. citizens, and there are no restrictions on applicant age, race, gender, or creed. Applicants can apply for more than one Grant.

Ineligibility

Applicants from non-academic facilities and postdoctoral positions are not eligible.